SBIR/STTR Research Award
Attenuated Shigella as Vector for Helicobacter Vaccine
Award amount
$86,331Program and phase
SBIR · Phase IAward year
1995Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Oravax, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Our goal is to develop a live vector vaccine against Helicobacter pylori by expression of urease inShigella flexneri 2A strains and testing the ability of these strains to induce a protective mucosalmice. Helicobacter pylori ureases will be expressed in attenuated S. flexneri strains to assess theoral vaccine vector. OraVax and others have demonstrated that oral immunization with H. pylori ureasprotective response against H. felis infection in mice when administered along with Cholera Toxin asAttenuated S. flexneri 2A (CVD1203) expressing urease will be constructed and used to immunize mice.immunity to Helicobacter infection will be assessed by subsequent challenge with H. felis. These expthe use of a live vector approach to immunization against H. pylori as an alternative to toxic mucosof these preliminary experiments will provide the basis for Phase II experiments using non-human priShigella and H. pylori to confirm the efficacy of live attenuated S. flexneri 2A strains as vaccine
Technology keywords
Not reported